CollectiveMinds LLC Places Robert Hollingsworth, PhD as Chief Scientific Officer of Protillion Biosciences [TheStreet.com]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: TheStreet.com
Next-generation life sciences executive search firm supports venture-backed antibody discovery company in securing life-changing scientific leadership HERNDON, Va. March 31, 2026 /PRNewswire/ -- CollectiveMinds LLC, a leading next-generation executive search firm specializing in life sciences and biotechnology, today announced the successful placement of Robert Hollingsworth, PhD, as Chief Scientific Officer of Protillion Biosciences, Inc. Protillion is an innovative, venture-backed biotechnology company headquartered in Carlsbad, California, backed by ARCH Venture Partners and Illumina Ventures. Dr. Hollingsworth is a seasoned drug development executive with more than 30 years of experience in the biotechnology and pharmaceutical industries. He most recently served as Chief Scientific Officer at Shoreline Therapeutics and previously held the role of Vice President and Chief Scientific Officer of Cancer Vaccines and Immunotherapeutics at Pfizer. Earlier in his career, he held sci
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer (PFE) is now covered by CICC Research. They set an "outperform" rating on the stock.MarketBeat
- UBS Adjusts Pharma Outlook, Increases Pfizer (PFE) Price Target [Yahoo! Finance]Yahoo! Finance
- Pfizer (PFE) had its price target raised by UBS Group AG from $25.00 to $27.00. They now have a "neutral" rating on the stock.MarketBeat
- Pfizer (PFE) had its price target raised by Morgan Stanley from $27.00 to $28.00. They now have an "equal weight" rating on the stock.MarketBeat
- Pfizer (PFE) had its price target lowered by Bank of America Corporation from $27.00 to $26.00. They now have a "neutral" rating on the stock.MarketBeat
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 4/16/26 - Form 4
- 4/10/26 - Form 3
- 4/1/26 - Form 4
- PFE's page on the SEC website